28 min
The What, When, Why and How of IDH Mutations in Cancer Embracing the Challenge - Advancing Cancer Care
-
- Medicine
In this PCPA podcast we discuss The What, When, Why and How of IDH Mutations in Cancer? The discussion covers the understanding of IDH mutations in cancer, a completely new enzyme driving cancer in both solid tumours and in haematology. Experts are on hand to cover the nuances in molecular testing and review current and future therapies and trends in these patient populations.
Dr Shehara Mendis, Medical Oncologist from Cabrini Hospital in Melbourne chairs this discussion with Dr Michael Rodriguez, Consultant Neuropathologist, St Vincent's Hospital and POW Hospital Sydney; Douglass Hanly Moir Pathology and Associate Professor Daniel Thomas, a Clinical Haematologist and Cancer Scientist from the University of Adelaide.
In this PCPA podcast we discuss The What, When, Why and How of IDH Mutations in Cancer? The discussion covers the understanding of IDH mutations in cancer, a completely new enzyme driving cancer in both solid tumours and in haematology. Experts are on hand to cover the nuances in molecular testing and review current and future therapies and trends in these patient populations.
Dr Shehara Mendis, Medical Oncologist from Cabrini Hospital in Melbourne chairs this discussion with Dr Michael Rodriguez, Consultant Neuropathologist, St Vincent's Hospital and POW Hospital Sydney; Douglass Hanly Moir Pathology and Associate Professor Daniel Thomas, a Clinical Haematologist and Cancer Scientist from the University of Adelaide.
28 min